Astellas (ALPMY.PK) and Medivation (MDVN) say a marketing approval application for enzalutamide...

|About: Astellas Pharma, Inc. ADR (ALPMY)|By:, SA News Editor

Astellas (ALPMY.PK) and Medivation (MDVN) say a marketing approval application for enzalutamide (its friends call it XTANDI and it's FDA approved) has been submitted to Japan's Ministry of Health, Labour, and Welfare for the treatment of prostate cancer. (PR)